# Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

> **NCT03720041** · PHASE3 · UNKNOWN · sponsor: **University of Leeds** · enrollment: 740 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm
- **DRUG:** R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm
- **DRUG:** R2: Lenalidomide plus placebo maintenance
- **DRUG:** R2: Lenalidomide + ixazomib maintenance

## Key facts

- **NCT ID:** NCT03720041
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-04
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 740 (ESTIMATED)
- **Last updated:** 2021-06-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720041, "Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03720041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*